Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04424901
Other study ID # 20-192-2.F
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date May 3, 2020
Est. completion date April 24, 2022

Study information

Verified date April 2023
Source UConn Health
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Brief Summary: The goal here is to evaluate dipyridamole in treating respiratory tract infection and circulatory dysfunction due to SARS-CoV-2 coronavirus in hospitalized CVID-19 patients. Infection with SARS-CoV-2 causes human COVID-19 (HCoV-19). The infection is associated with a deleterious inflammatory response and a prothrombotic state in addition to tissue damage from direct viral entry and proliferation. Dipyridamole has anti-platelet and anti-inflammatory effects. The drug was recently demonstrated to have anti-SARS-Cov-2 effect primarily in vitro. The concentration causing anti-viral effect in vitro is within that in the blood of humans taking this drug. As an oral tablet, it has the advantage of easy administration. Anti thrombotic, anti viral and anti inflammatory actions of this drug may be efficacious and safe in hospitalized subjects


Description:

The original protocol stipulated an enrollment of 100 patients, randomized in a 1 to 1 distribution of treatment versus control [placebo] group. However, the study was terminated because of insufficient enrollment due to the dramatic reduction in the number of hospitalized COVID patients. A total of 41 patients were randomized prior to study termination. Detailed reports and overall results were reviewed for all patients. Adverse event occurrences were similar in groups. Given the severity of COVID, these numbers were not unexpected. The DSMC concluded that all the AEs seen in study subjects are either unrelated or probably unrelated to the TOLD study intervention. The DSMC reviewed the primary outcome results. No statistically significant change in either the platelet count or the D-dimer results.


Recruitment information / eligibility

Status Terminated
Enrollment 41
Est. completion date April 24, 2022
Est. primary completion date March 22, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Adults =18 years of age. 2. COVID-19 positive by PCR and hospitalized for respiratory infection with a range of respiratory severity as follows. Moderate ? Diagnosed with SARS-CoV-2 infection by standard RT-PCR assay or equivalent testing ? Symptoms of moderate illness with COVID-19, which could include: o Fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms; shortness of breath with exertion - Clinical signs suggestive of moderate illness with COVID-19, such as: o RR = 20, HR = 90, SaO2 =93% on room air or requires =2L oxygen by nasal cannula (NC) in order maintain SaO2 =93%, fever >38.3 Celsius - No clinical signs indicative of Severe or Critical Illness Severity Severe - Diagnosed with SARS-CoV-2 infection by standard RT-PCR assay or equivalent testing - Symptoms suggestive of severe systemic illness with COVID-19, which could include: o any symptom of Moderate Illness; shortness of breath at rest or respiratory distress - Clinical signs indicative of severe systemic illness with COVID-19, such as o RR = 30, HR = 125, requires > 2L oxygen by NC in order maintain SaO2 =93%, PaO2/FiO2 <300 - No criteria for Critical Severity Critical ? Diagnosed with SARS-CoV-2 infection by standard RT-PCR assay or equivalent testing - Evidence of critical illness, defined by at least 1 of the following: - Respiratory failure defined based on resource utilization requiring at least 1 of the following: ?, Oxygen delivered by high-flow nasal cannula (heated, humidified, oxygen delivered via reinforced nasal cannula at flow rates >20L/min with fraction of delivered oxygen =0.5), noninvasive positive pressure ventilation, ECMO, or clinical diagnosis of respiratory failure (i.e., clinical need for one of the preceding therapies, but preceding therapies not able to be administered in setting of resource limitation) - Shock (defined by SBP < 90 mm Hg, or Diastolic BP < 60 mm Hg or requiring vasopressors) - Multiple organ dysfunction/failure 3. Able to give written informed consent in English to participate in the study by patient. - Exclusion Criteria: - Exclusion Criteria: 1. Inability to swallow or ingest oral medication in either tablet form or in suspension form. 2. Patient is known to be pregnant 3. Patients with a history of allergy or hypersensitivity to dipyridamole 4. Patient is unable to consent -intubated, on mechanical ventilation 5. Bleeding disorders (e.g. thrombocytopenia with platelet counts < 50,000) 6. Existing severe medical illnesses unrelated to Covid-19 infection such as end stage heart, kidney, liver disorders; or hepatic insufficiency defined as liver enzymes =5 times upper limit normal if baseline is normal or 5 times baseline if baseline is abnormal. Metastatic cancer as well as those with severe coronary artery disease, unstable angina, STEMI, NSTEMI, hypotension (systolic blood pressure <90mmHg), myocarditis, bradycardia with resting heart rate less than 60 bpm, atrioventricular block without pacemaker. Those with myasthenia gravis and those treated with cholinesterase inhibitors 7. Patient is enrolled in a clinical trial for another investigational drug designed to test for efficacy for SARS-CoV-2

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Placebo
Daily dose while hospitalized up to 9 days
Dipyridamole Tablets
Daily dose while hospitalized up to 9 days

Locations

Country Name City State
United States UConn Health Farmington Connecticut

Sponsors (1)

Lead Sponsor Collaborator
UConn Health

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Survival Survival Status Alive 9 days
Other Inflammatory Markers Change in the markers CRP/Ferritin 9 days
Other Blood Markers Change in Lymphocyte Count/ Fibrinogen/Cardiac Troponin 9 days
Other PT PTT Coagulation System 9 days
Other Pulmonary Status Change in SpO2/ imaging 9 days
Other Clinical Status Change in fever, cough, sputum 9 days
Primary D-dimer Percent Change from Baseline [Day Zero] to last study measure (Day 3, Day 6 or Day 9) up to 9 days
Primary Platelet Count Percent Change from Baseline [Day Zero] to last study measure (Day 3, Day 6 or Day 9) up to 9 days
Secondary Viral Detection Evaluate for a non-detection from nasopharyngeal swab and in stool 9 days
See also
  Status Clinical Trial Phase
Suspended NCT04901676 - Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia Phase 3
Not yet recruiting NCT04534478 - Oral Prednisone Regimens to Optimize the Therapeutic Strategy in Patients With Organizing Pneumonia Post-COVID-19 Phase 4
Active, not recruiting NCT05002517 - Randomized, Unicentric, Open, Controlled Clinical Trial, in Phase Iii, to Demonstrate the Effectiveness of Tocilizumab Phase 3
Completed NCT05008393 - Efficacy of PJS-539 for Adult Patients With COVID-19. Phase 2
Completed NCT04569877 - GM-CSF Inhalation to Prevent ARDS in COVID-19 Pneumonia Phase 2
Not yet recruiting NCT05286255 - Mesenchymal Stromal Cells for COVID-19 and Viral Pneumonias Phase 1
Completed NCT05035589 - The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia
Completed NCT06113432 - CPAP Therapy Through a Helmet or a Full Face Mask in Patients With Acute Hypoxemic Respiratory Failure: Cross-over Study N/A
Recruiting NCT05042063 - Acoustic Cough Monitoring for the Management of Patients With Known Respiratory Disease
Recruiting NCT04615429 - Clinical Trial to Assess the Efficacy of MSC in Patients With ARDS Due to COVID-19 Phase 2
Completed NCT05047653 - RALE Versus CORADS/CT-Severity Score in COVID-19
Active, not recruiting NCT05047016 - Study to Evaluate the Dynamic Consent Model Based on the Blockchain-based Clinical Trial Platform METORY N/A
Active, not recruiting NCT05033847 - Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above Phase 2
Recruiting NCT06113757 - Investigation of Efficacy and Safety of Electrical Signal Therapy Provided by Dr Biolyse® Device in COVID-19 Disease N/A
Completed NCT05504655 - N-Acetylcysteine as an Adjuvant Therapy in Critically Ill COVID-19 Patients:
Active, not recruiting NCT05035524 - A Randomized Controlled Trial to Investigate The Role of Adjuvant Inhalable Sodium Bicarbonate Solution 8.4% in Treatment of COVID-19 N/A
Completed NCT05065879 - Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes Phase 4
Withdrawn NCT04390217 - LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia Phase 2
Withdrawn NCT04460105 - Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia Phase 1
Suspended NCT04901689 - Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation Phase 3